Navigation Links
Dehaier Medical Systems Continues Product Line Expansion. Signs Exclusive Distribution Agreement with HEYER Medical for Respiratory Products in China
Date:5/24/2010

, "Our new partnership with HEYER Medical further supplements our product line for treatment of respiratory diseases. This not only provides Dehaier with additional highly sophisticated products, but also widens the experience of our marketing and service teams. This exclusive agreement provides us with access to the market segment in China for nebulizer products, which we estimate to be about $30 million per year. The Cumulus is an ideal product addition to our Homecare Medical Products segment that already includes homecare ventilators, oxygen generators, sleep screening systems and our Dehaier rhinitis hyperthermia device.

"We estimate that on a global basis, the fast growing market for respiratory and oxygen homecare products is in excess of $2.0 billion per year," Chen said.

About HEYER Medical AG

HEYER was founded in 1883 in Germany and has become an innovator in inhalation technology for the treatment of respiratory tract diseases. Today HEYER is an internationally acknowledged specialist in state-of-the-art inhalation and anesthesia medical equipment, oxygen concentrators, breathing therapy equipment and connecting equipment. HEYER products are used all over the world, particularly in the medical field, in clinics and practices in Europe and Asia as well as in the Middle East, South America and the USA. Our inhalation equipment is also increasingly used in wellness applications and for treatment and care at home. Website

SOURCE Dehaier Medical Systems Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
3. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
4. Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth
5. BioMS Medical announces its intention to renew a normal course issuer bid
6. Dr. Amit Dhawan Promoted to Medical Director for The Mattson Jack Group
7. ATS Medical Expands Open Pivot Heart Valve Offerings
8. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
9. Globus Medical Announces Record 2nd Quarter 2007 Results
10. IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development
11. China Medical Technologies Reports First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... January 14, 2014 Date: Friday, April 11, ... Warrington Country Club, 1360 Almshouse Road, Warrington, Pa. ... organization solely dedicated to finding a cure for hepatitis B ... will host its annual Crystal Ball on Friday, April 11 ...
(Date:1/14/2014)... York, NY (PRWEB) January 14, 2014 ... of Alliqua, Inc. (OTCQB: ALQA). Alliqua is an emerging ... to serve the wound care market. , Free report ... was restructured with a seasoned management team and Board, ...
(Date:1/14/2014)... Mass. , Jan. 14, 2014  RXi Pharmaceuticals ... discovering, developing and commercializing innovative therapies addressing major ... that it received the Notice of Allowance from ... its unique self-delivering RNAi compounds (sd-rxRNA®), for the ...
(Date:1/14/2014)... NY (PRWEB) January 14, 2014 During the ... now known as “The Doctor’s Plague.” In this time period, ... hands. This led, at times, to the death of vulnerable ... today don’t know that they may be unwittingly transmitting herpes ...
Breaking Biology Technology:Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3
... to be Used for Advancement of Cancer Stem Cells and Other ... ... MacroGenics, Inc., a privately,held biotechnology company that develops immunotherapeutics to treat,autoimmune ... million in a Series D-2 financing. The round, led by,Nextech Venture, ...
... COLLINS, Colo., Sept. 24 InVitria,( http://www.InVitria.com ... Annual "Optimizing Cell Culture Development" Conference on,September ... most recent,results optimizing cell culture media using ... ingredients.,( http://www.healthtech.com/ocb/overview.aspx?c=562 ), In a presentation ...
... combats an,alarming rise in chronic diseases, the Pharmaceutical ... new report on the next,generation of medicines in ... The report found that America,s pharmaceutical research ... - are,testing a record 633 new biotech medicines., ...
Cached Biology Technology:MacroGenics Raises $25M in Series D-2 Financing 2MacroGenics Raises $25M in Series D-2 Financing 3MacroGenics Raises $25M in Series D-2 Financing 4InVitria Touts Product Advantages at Cambridge's Cell Culture Conference 2New Report on 633 Biotechnology Medicines Under Development Released in Michigan 2New Report on 633 Biotechnology Medicines Under Development Released in Michigan 3
(Date:4/24/2014)... April 24, 2014GEN Publishing recently introduced ... focusing on the application of OMICs technologies in ... sequencing, are beginning to transform medical care just ... the past decade-and-a-half. , "GEN,s editors and reporters ... genomics, metabolomics, transcriptomics, etc. etc. for years," said ...
(Date:4/24/2014)... April 24, 2014D-ribose is a commercially important sugar ... as a starting compound for synthesizing riboflavin and ... coli to increase the bacteria,s ability to ... more efficient industrial-scale production of this valuable chemical, ... Biotechnology , a peer-reviewed journal from Mary Ann ...
(Date:4/24/2014)... in the Scientific Reports journal. , CSIC researcher ... centre of CSIC and Pompeu Fabra University-UPF), explains: "When the ... saw that it did not match with the DNA recovered ... complete genome and to make a functional interpretation in order ... XVI". , The functional genome analysis was based on ...
Breaking Biology News(10 mins):The blood preserved in the pumpkin did not belong to Louis XVI 2
... SILVERTHORNE, CO December 11, 2009 Keystone ... announce the appointment of five new Keystone Symposia Fellows ... five talented early-career life scientists (postdoctoral trainees or assistant ... for one year. Fellows are selected based on their ...
... Obese patients who lost a moderate amount of weight by ... a study at Washington University School of Medicine in St. ... the Dec. 15, 2009, issue of the Journal of ... led to improvement in four key measures of heart and ...
... , This release is available in ... richness, due to more plant introductions than extinctions, plant ... The same species are occurring more frequently, whereas rare ... biological communities that are becoming increasingly similar, but also ...
Cached Biology News:Keystone Symposia appoints 5 Fellows as part of diversity in life science initiative 2Keystone Symposia appoints 5 Fellows as part of diversity in life science initiative 3Keystone Symposia appoints 5 Fellows as part of diversity in life science initiative 4Moderate weight loss in obese people improves heart function 2Moderate weight loss in obese people improves heart function 3Europe's flora is becoming impoverished 2Europe's flora is becoming impoverished 3
... Mouse C2C12 cells were cultured in DMEM and ... In order to keep the antigens in their ... The cells are arrayed on a 12-well (5 ... specifically treated to enhance cellular attachment and to ...
... Sample Buffer is a convenient, ... experimental samples and Perfect RNA ... needs no dilution and is ... gels. Simply mix equal volumes ...
... cells were cultured in DMEM and harvested at ... to keep the antigens in their native forms, ... are arrayed on a 12-well (5 mm) adhesive ... to enhance cellular attachment and to minimize background ...
... CopyControl™ vector can be induced prior to ... provide the stability of single-copy BACs with ... other cloning vectors. The kits provide the ... insert size screening system) necessary to create ...
Biology Products: